Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

PLYX Total Current Assets

All assets expected to be converted to cash or used up within one year.

Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX

Total Current Assets · Q1 FY2026 · quarter ended Mar 2026

Total current assets falls 21.1% from a year ago

Total current assets stood at $3.5M at the end of Q1 FY2026, down 21.1% from a year earlier and down 32.3% from the prior quarter.

Context

  • Total current assets amounted to 100.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Total current assets increased in 2 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether total current assets keeps falling in the next quarterly balance sheet after a -21.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.5M-32.3% QoQ
Last fiscal yearDec 2025
$5.17M+3.4% YoY
Year agoMar 2025
$4.44M-21.1% since
Total Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.1%——
1 year+3.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Current Assets history

USD · from the balance sheet

Latest · FY2025
5.17M USD
Year-over-year change
+3.4%
2-year CAGR
+49.4%

Total Current Assets vs competitors

How PLYX compares with its peers on the latest reported figures

  • PLYX's Mar 2026 total current assets of $3.5M is the lowest of the 8 companies compared; the peer median is $188.06M.
  • Its year-over-year change of -21.1% is the lowest of 8, against a peer median of +25.8%.
  • Total current assets amounts to 100.0% of total assets for PLYX, versus a peer median of 89.3%.
PLYX Competitors Peer median
Total Current Assets for PLYX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
JBIOJade Biosciences, Inc.Mar 2026$318.52M +311.7%+36.7%99.7%
LYELLyell Immunopharma, Inc.Mar 2026$267.3M -13.5%-26.3%76.2%
CBIOCrescent Biopharma, Inc.Mar 2026$195.56M +3163.6%+67.1%98.2%
FHTXFoghorn Therapeutics Inc.Mar 2026$188.06M -16.6%-22.6%84.6%
KLRSKalaris Therapeutics IncMar 2026$98.08M -4.0%+212.3%89.3%
ANTXAN2 Therapeutics, Inc.Mar 2026$87.49M +25.8%-15.3%100.0%
PTHSPelthos Therapeutics Inc.Mar 2026$69.09M +7482.5%+885.4%47.5%
PLYXPolaryx Therapeutics, Inc. Common StockMar 2026$3.5M -21.1%—100.0%
Peer median (excluding PLYX) $188.06M+25.8%+36.7%89.3%

Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Intrinsic Alpha fair value

Locked

Current Price

$1.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.